Keros Therapeutics Inc. is a renowned clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients with hematological and musculoskeletal disorders. The company trades under the stock symbol "KROS" on the NASDAQ stock exchange.
Based in Lexington, Massachusetts, Keros is among the leaders in utilizing novel computational methods to identify unique therapeutic approaches to address imbalances in signaling pathways involved in these disorders. The company's passionate team of scientists, clinicians, and biotechnology veterans strives to make a meaningful impact in the healthcare industry by helping improve patients' lives through their pioneering work.
The firm operates with a focus on three core therapeutic areas: Pulmonary, Hematology, and Musculoskeletal disorders. One of the company's lead product candidates is KER-050, an engineered ligand trap designed to increase red and white blood cell counts. It is being developed initially to treat patients with low blood cell counts, either from diseases, such as myelodysplastic syndromes, or from receiving chemotherapy.
Keros' product candidate, KER-047, is being developed for the treatment of anemia or iron overload related to certain inflammatory conditions as well as for treating fibrodysplasia ossificans progressiva, a rare genetic condition that causes muscle tissue and other connective tissues to transform into bone.
A key aspect differentiating Keros from other comparable biopharmaceutical companies is its commitment to in-depth research and development using their proprietary platform. It brings together deep biological insights, sophisticated computational methods and cutting-edge experimental techniques to address these challenging diseases.
Perhaps what is most exciting about Keros is its promise for the future. With some of its innovative therapies in clinical trial phases, Keros is positioning itself at the forefront of finding potential solutions to several unmet medical needs. Its continuous innovative strides in the field reiterate the company's dedication to providing valuable solutions that will ultimately improve patient care.
In summary, Keros Therapeutics, Inc. represents a blend of deep research, innovative spirit, and a sincere commitment to improve patient care, making it a noteworthy player in the biopharmaceutical landscape. As it continues to progress its product candidates through clinical development, the company is poised for significant growth in the coming years.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Keros Therapeutics, Inc. (KROS) is highlighted as a compelling investment opportunity in the biotechnology sector, boasting a potential upside of 74.59%. The company, a clinical-stage biopharmaceutical firm, is developing therapeutics for disorders related to transforming growth factor-beta family proteins. Despite not yet being profitable, its innovative pipeline, strategic collaborations with Hansoh and Takeda, and favorable analyst ratings position it as a noteworthy stock for long-term growth-oriented investors.
This article analyzes Keros Therapeutics Inc. (NASDAQ: KROS) through volatility zones, identifying stable neutral readings in shorter horizons and a mid-channel oscillation pattern. It highlights an exceptional 95.3:1 risk-reward setup targeting a 29.6% gain, alongside neutral sentiment. The analysis provides specific institutional trading strategies for long, breakout, and short positions, based on AI-generated signals and multi-timeframe analysis.
Bank of New York Mellon Corp has acquired a new position in Keros Therapeutics, Inc., purchasing 103,339 shares valued at approximately $1.11 million. This comes as Keros Therapeutics reported a quarterly loss worse than anticipated and authorized a $5 million share repurchase program. Analysts currently maintain a "Hold" rating on the stock with an average price target of $20.50.
Keros Therapeutics' Board of Directors has approved a $5 million share repurchase program, authorizing the company to buy back up to 2.3% of its outstanding shares. This decision comes as KROS shares trade near the midpoint of their 52-week range, despite the company reporting a wider-than-expected quarterly loss. Analyst sentiment for Keros Therapeutics remains mixed, with an average "Hold" rating and a price target of $20.50, though some recent targets have been lowered.
Keros Therapeutics, Inc. has announced a share repurchase program, authorizing the buyback of up to $5 million worth of its common stock. This decision was published on September 8, 2026, at 04:03 pm EDT. The biotechnology company focuses on developing therapeutics for disorders related to dysfunctional TGF-beta family proteins.
Keros Therapeutics announced a $5 million share repurchase authorization following a $20 million milestone payment from Takeda Pharmaceuticals for elritercept's ELRiSE MDS clinical trial. The program allows Keros to repurchase common stock in the open market, with timing and amount dependent on market conditions and other factors. Keros is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for disorders related to dysfunctional TGF-ß family proteins.
Empowered Funds LLC has acquired a new position in Keros Therapeutics, Inc. (NASDAQ:KROS) by purchasing 142,151 shares valued at approximately $1.52 million during the second quarter of 2026. This investment makes Empowered Funds LLC a 0.72% owner of Keros Therapeutics, a company where institutional investors collectively hold 71.56% of the stock. Keros Therapeutics recently reported a quarterly loss that missed analyst expectations, and despite mixed analyst ratings, the stock holds an overall "Hold" consensus with an average price target of $20.50.